All News
Filter News
Found 736 articles
-
Scandion Oncology, Edesa, Clovis, Lexicon and Cytokinetics share a string of positive news from their clinical trials on heart failure, cancer, COVID-19 and ARDS.
-
New Analysis of SOLOIST-WHF Trial Underscores Sotagliflozin’s Effect on Reducing Recurrent Heart Failure Events
10/2/2022
Lexicon Pharmaceuticals, Inc. announced that a new analysis of results from the SOLOIST-WHF Phase 3 outcomes trial of sotagliflozin, an investigational dual SGLT1 and SGLT2 inhibitor, was presented at the Heart Failure Society of America Annual Scientific Meeting 2022.
-
Lexicon Pharmaceuticals Highlights Scientific and Medical Presentations Relating to Its Successful Phase 2 Proof-Of-Concept Study of LX9211 in Painful Diabetic Neuropathy
9/20/2022
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced a series of scientific and medical presentations describing the progression of its investigational drug LX9211 from discovery to translation in a clinical proof-of-concept study.
-
Biopharma and life sciences companies, such as Seraxis, Verily and Vaxart, tap new members to bolster their leadership teams in roles like CMO, CTO, CCO, and more.
-
Seraxis Announces Appointment of Chief Medical Officer, Dr. Paul Strumph
8/30/2022
The regenerative medicine company Seraxis Inc. announced the appointment of Paul Strumph, M.D. as Chief Medical Officer.
-
Lexicon Pharmaceuticals Highlights Publications Relating to Sotagliflozin's Differentiated Dual SGLT1 and SGLT2 Mechanism of Action and Potential Implications for Cardiovascular Disease
8/22/2022
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced a series of publications concluding that sotagliflozin’s differentiated dual SGLT1 and SGLT2 mechanism of action may have implications for cardiovascular disease.
-
Lexicon Announces Full Exercise and Closing of Options to Purchase Additional Shares in Connection with Previously Announced Public Offering and Concurrent Private Placement
8/5/2022
Lexicon Pharmaceuticals, Inc. announced the issuance and sale of an additional 2,526,540 shares of its common stock, par value $0.001, pursuant to the full exercise of the underwriters’ option to purchase additional shares in connection with Lexicon’s previously announced public offering of Common Stock.
-
Lexicon Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update
8/2/2022
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended June 30, 2022 and provided an update on key milestones.
-
Arvinas Appoints John Northcott as Chief Commercial Officer
8/1/2022
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that John Northcott has joined the company in a newly created position of Chief Commercial Officer (CCO).
-
Lexicon Pharmaceuticals to Host Second Quarter 2022 Financial Results Conference Call and Webcast on August 2, 2022
7/29/2022
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), will release its second quarter 2022 financial results on Tuesday, August 2, 2022 after the markets close. Management will conduct a conference call and live webcast at 5:00 p.m. ET / 4:00 p.m. CT that day to discuss its financial and operating results and to provide a general business update.
-
Lexicon Announces Pricing of $85.0 Million Public Offering and Concurrent Private Placement
7/28/2022
Lexicon Pharmaceuticals, Inc. announced the pricing of its previously announced underwritten public offering of 16,843,600 shares of its common stock, par value $0.001.
-
Lexicon Announces FDA Acceptance of New Drug Application for Sotagliflozin to Treat Heart Failure
7/27/2022
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review and filed its New Drug Application (NDA) for sotagliflozin.
-
Lexicon Announces Proposed Public Offering Of Common Stock - July 27, 2022
7/27/2022
Lexicon Pharmaceuticals, Inc. announced that it has commenced an underwritten public offering to offer and sell, subject to market and other conditions, shares of its common stock, par value $0.001.
-
Carcinoid Syndrome Diarrhea Treatment Market Demand, Insights and Forecast up to 2027
7/27/2022
Wilmington, Delaware, United States, Transparency Market Research Inc.: Carcinoid syndrome is a combination of symptoms such as abnormal laboratory finding and physical manifestation.
-
Gout Therapeutics Market, 2031 | Current Trends | Regional Outlook | Competitive Landscape
7/26/2022
The objective of treatment during a severe gout attack involves suppressing inflammation and controlling pain.
-
Otsuka and Lunbeck report positive Phase III results in agitation in Alzheimer's, Acer's vEDS program hits Phase III and BridgeBio's primary hyperoxaluria type 1 program progresses.
-
Capping off the first half of the year is a flurry of clinical trial wins. BioSpace takes a look at some of the most exciting ones:
-
Lexicon Announces Positive Top-Line Results From Phase 2 Proof-Of-Concept Study Of LX9211 In Painful Diabetic Neuropathy
6/29/2022
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced top-line results of RELIEF-DPN-1, its Phase 2 proof-of-concept study of LX9211 in painful diabetic neuropathy.
-
Lexicon Pharmaceuticals to Participate in the Jefferies 2022 Healthcare Conference
6/1/2022
Lexicon Pharmaceuticals, Inc. announced that Lonnel Coats, Lexicon’s chief executive officer, will present at the Jefferies 2022 Healthcare Conference on Wednesday, June 8, 2022 at 10:00 a.m. ET.
-
Lexicon Resubmits New Drug Application for Sotagliflozin for the Treatment of Heart Failure
5/31/2022
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it has resubmitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for the marketing and sale of sotagliflozin for the treatment of heart failure.